Design, Synthesis and Molecular Docking Studies of Novel Triazole‐Chromene Conjugates as Antitubercular, Antioxidant and Antifungal Agents

Abstract

AbstractA green and efficient protocol has been developed for the synthesis of novel 1,2,3‐triazole‐chromene conjugates (7 a‐j) via ultrasound assisted and NaHCO3 catalyzed for the first time. Structures of all the new conjugates were deduced by various spectroscopic techniques. The newly synthesized triazole‐chromene conjugates were evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis (MTB) H37Rv strain. The conjugates 7 f and 7 h were found to be most active with MIC value 12.5 μg/mL. Furthermore, all the conjugates were screened for their antioxidant activity and are highly active (IC50=7.05‐14 μg/mL) than the reference drug BHT (16.47 μg/mL). The triazole‐chromene conjugates were also screened for their in vitro antifungal activity and some of the conjugates 7 a, 7 b, 7 d, 7 e, 7 f and 7 i were exhibited potent activity (MIC=6.25‐25 μg/mL) than the reference drug Miconazole. Docking studies showed significant binding affinity in the active site of Mycobacterium tuberculosis DprE1 enzyme.